A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4384-4391

  Yan, Luo ^a   Bertarelli, Daniela C G ^a   Hayallah, Alaa M ^a,b   Meyer, Heiko ^a   Klotz, Karl Norbert ^c   Müller, Christa E ^a,d  

^a UNIVERSITY OF BONN   (Germany)

^b Assiut University   (Egypt)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Pharmazeutisches Institut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOXYSULFONYLPHENYLXANTHINE DERIVATIVE; 4 NITROPHENYLSULFONATE DERIVATIVE; 8 [4 (4 BENZYLPIPERAZIDE 1 SULFONYL)PHENYL] 1 PROPYLXANTHINE; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; AMINE; ANILINE DERIVATIVE; BENZYLAMINE; BUTYLAMINE; ETHANOLAMINE; GLYCINE; N BENZYLPIPERAZINE; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROPYLAMINE; PSB 601; RECEPTOR SUBTYPE; SULFONAMIDE; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

AMINOLYSIS; ARTICLE; CHEMICAL REACTION KINETICS; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; MOLECULAR STABILITY; STRUCTURE ANALYSIS;

ANIMALS; ARYLSULFONATES; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A2B; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XANTHINES;

EID: 33745836712     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060277v     Document Type: Article

References (54)

1. Abraham, D. J., Ed. Burger's Medicinal Chemistry & Drug Discovery; John Wiley and Sons: Hoboken, NJ, 2003.
2. Wu, C.; Decker, E. R.; Holland, G. W.; Brown, F. D.; Stavros, F. D.; Brock, T. A.; Dixon, R. A. C. Nonpeptide endothelin antagonists in clinical development. Drugs Today 2001, 37, 441-453.
3. De Clercq, E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 2001, 8, 1543-1572.
4. Rotella, D. P. Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat. Rev. Drug Discovery 2002, 1, 674-682.
5. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkerl, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
6. Müller, C. E.; Stein, B. Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr. Pharm. Des. 1996, 2, 501-530.
7. 2-adenosine receptors. J. Med. Chem. 1985, 28, 487-492.
8. Hamilton, H. W.; Ortwine, D. F.; Worth, D. F.; Badger, E. W.; Bristol, J. A.; Bruns, R. F.; Haleen, S. J.; Steffen, R. P. Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. J. Med. Chem. 1985, 28, 1071-1079.
9. 2A-selective adenosine receptor antagonists. Bioorg. Med. Chem. 1998, 6, 707-719.
10. 2B-selective adenosine receptor antagonists. J. Med. Chem. 2002, 45, 1500-1510.
11. 2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 2004, 308, 358-366.
12. 2B adenosine receptors. Curr. Top. Med. Chem. 2003, 3, 427-443.
13. 2B Adenosine receptor antagonists: Recent developments. Mini-Rev. Med. Chem. 2005, 5, 499-505.
14. Zhong, H.; Belardinelli, L.; Maa, T.; Feoktistov, I.; Biaggioni, I.; Zeng, D. A2b Adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 2004, 30, 118-125.
15. Link, J. T. Pharmacological regulation of hepatic glucose production. Curr. Opin. Invest. Drugs 2003, 4, 421-429.
16. 2B receptor. J. Med. Chem. 2001, 44, 170-179.
17. Fozard, J. R.; McCarthy, C. Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Invest. Drugs 2002, 3, 69-77.
18. 2B adenosine receptor functioning by tumour necrosis factor α in human astroglial cells. J. Neurochem. 2004, 91, 1180-1190.
19. 2B receptor as a novel therapeutic target in asthma. Br. J. Pharmacol. 2005, 145, 1009-1015.
20. 2B receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J. Neurochem. 1996, 66, 1426-1431.
21. Yan, L.; Müller, C. E. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: Toward the development of sulfonic acid prodrugs with peroral bioavailability. J. Med. Chem. 2004, 47, 1031-1043.
22. 2B adenosine receptor. J. Med. Chem. 2006, 49, 282-299.
23. 2B. Eur. J. Med. Chem. 2004, 39, 879-887.
24. 2B receptors. Bioorg. Med. Chem. 2003, 11, 77-85.
25. 2B adenosine receptor subtypes: a molecular modeling investigation. J. Med. Chem. 2003, 46, 4287-4296.
26. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J. Med. Chem. 2002, 45, 2131-2138.
27. 2B receptors. Biochem. Pharmacol. 2005, 70, 1601-1612.
28. 2B adenosine receptor antagonists. J. Med. Chem. 2004, 47, 1434-1447.
29. 2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg. Med. Chem. Lett. 2005, 15, 609-612.
30. Smith, M. B., Ed. March's Advanced Organic Chemistry; John Wiley and Sons Inc.: New York, 2001.
31. 3 adenosine receptor and molecular modeling studies. J. Med. Chem. 2001, 44, 2735-2742.
32. Decat, A.; Pouke, R. V.; Verbrugghe, M. J. Sulfonyl fluorides as intermediates in organic synthesis. II. Synthesis and alkaline hydrolysis of 2-(acylacetyl)aminothiazoles containing fluorosulfonyl substituents. J. Org. Chem. 1965, 30, 1498-1502.
33. Kruse, C. H.; Holden, K. G.; Pritchard, M. L.; Field, J. A.; Rieman, D. J.; Grieg, R. G.; Poste, G. Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 1. J. Med. Chem. 1988, 31, 1762-1767.
34. Hanna, N. B.; Dimitrijevich, S. D.; Larson, S. B.; Robins, R. K.; Revankar, G. R. Synthesis and single-crystal X-ray diffraction studies of 1-β-D-ribofuarnosyl-1,2,4-triazole-3-sulfonamide and certain related nucleosides. J. Heterocyd. Chem. 1988, 25, 1857-1868.
35. Choi, J. H.; Lee, B. C.; Lee, H. W.; Lee, I. Head-to-backbone cyclization of peptides on solid support by nucleophilic aromatic substitution. J. Org. Chem. 2002, 67, 1277-1281.
36. Cain, G. A.; Beck, J. P. Unsymmetrical 4,6-diamino-2-methyl-5- nitropyrimidine synthesis via 4,6-bis(tosylates). Heterocycles 2001, 55, 439-446.
37. Caddick, S.; Wilden, J. D.; Bush, H. D.; Wadman, S. N.; Judd, D. B. A new route to sulfonamides via intermolecular radical addition to pentafluorophenyl vinylsulfonate and subsequent aminolysis. Org. Lett. 2002, 4, 2549-2551.
38. Caddick, S.; Wilden, J. D.; Judd, D. B. Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids. J. Am. Chem. Soc. 2004, 126, 1024-1025.
39. Bulicz, J.; Bertarelli, D. C. G.; Baumert, D.; Fülle, F.; Müller, C. E.; Heber, D. Synthesis and pharmacology of pyrido[2,3-d] pyrimidinediones bearing polar substituents as adenosine receptor antagonists. Bioorg. Med. Chem. 2006, 14, 2837-2849.
40. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J. Med. Chem. 2002, 45, 2131-2138.
41. 2A-selective adenosine receptor antagonists. J. Med. Chem. 2000, 43, 440-448.
42. Song, X.; Vig, B. S.; Lorenzi, P. L.; Drach, J. C.; Townsend, L. B.; Amidon, G. L. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J. Med. Chem. 2005, 48, 1274-1277.
43. Daly, J. W. In Role of Adenosine and Adenine Nucleotides in the Biological System; Imai, S., Nakazawa, M., Eds.; Elsevier Science Publishers: New York, 1991; p 119.
44. 2B adenosine receptors. Drug Dev. Res. 1999, 47, 45-53.
45. 3 adenosine receptor with widespread tissue distribution. Mol. Pharcacol. 1993, 44, 524-532.
46. Müller, C. E.; Shi, D.; Manning, M.; Daly, J. W. Synthesis of paraxanthine analogues (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: Structure-activity relationships at adenosine receptors. J. Med. Chem. 1993, 36, 3341-3349.
47. 1 receptor antagonists. J. Med. Chem. 2004, 47, 6529-6540.
48. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediciton of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999, 88, 807-814.
49. Viswanadhan, V. N.; Chose, A. K.; Revankar, G. R.; Robins, R. K. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
50. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
51. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.
52. 2B receptors. Biochem. Pharmacol. 2004, 68, 305-312.
53. 1-Adenosine receptor antagonists. Exp. Opin. Ther. Pat. 1997, 7, 419-440.
54. 2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 302-306.